[Pegylated-interferon-induced diabetes mellitus type 1 in two patients with chronic hepatitis C].
Primo Vera
J
J
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced* / Q000276:immunology; D005968:Glutamate Decarboxylase / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000276:immunology; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use
D000998:Antiviral Agents; D001323:Autoantibodies; D001324:Autoantigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D005968:Glutamate Decarboxylase; C100416:peginterferon alfa-2a